Abstract
Background: Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. Methods: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 until 2030. We report all spending estimates in inflation-adjusted 2019 US$, unless otherwise stated. Findings: Since the development and implementation of the SDGs in 2015, global health spending has increased, reaching $7·9 trillion (95% uncertainty interval 7·8–8·0) in 2017 and is expected to increase to $11·0 trillion (10·7–11·2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was $20·2 billion (17·0–25·0) and on tuberculosis it was $10·9 billion (10·3–11·8), and in malaria-endemic countries spending on malaria was $5·1 billion (4·9–5·4). Development assistance for health was $40·6 billion in 2019 and HIV/AIDS has been the health focus area to receive the highest contribution since 2004. In 2019, $374 million of DAH was provided for pandemic preparedness, less than 1% of DAH. Although spending has increased across HIV/AIDS, tuberculosis, and malaria since 2015, spending has not increased in all countries, and outcomes in terms of prevalence, incidence, and per-capita spending have been mixed. The proportion of health spending from pooled sources is expected to increase from 81·6% (81·6–81·7) in 2015 to 83·1% (82·8–83·3) in 2030. Interpretation: Health spending on SDG3 priority areas has increased, but not in all countries, and progress towards meeting the SDG3 targets has been mixed and has varied by country and by target. The evidence on the scale-up of spending and improvements in health outcomes suggest a nuanced relationship, such that increases in spending do not always results in improvements in outcomes. Although countries will probably need more resources to achieve SDG3, other constraints in the broader health system such as inefficient allocation of resources across interventions and populations, weak governance systems, human resource shortages, and drug shortages, will also need to be addressed. Funding: The Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 693-724 |
Number of pages | 32 |
Journal | The Lancet |
Volume | 396 |
Issue number | 10252 |
DOIs | |
Publication status | Published - 5 Sept 2020 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 396, No. 10252, 05.09.2020, p. 693-724.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health
T2 - progress towards Sustainable Development Goal 3
AU - Global Burden of Disease Health Financing Collaborator Network
AU - Micah, Angela E.
AU - Su, Yanfang
AU - Bachmeier, Steven D.
AU - Chapin, Abigail
AU - Cogswell, Ian E.
AU - Crosby, Sawyer W.
AU - Cunningham, Brandon
AU - Harle, Anton C.
AU - Maddison, Emilie R.
AU - Moitra, Modhurima
AU - Sahu, Maitreyi
AU - Schneider, Matthew T.
AU - Simpson, Kyle E.
AU - Stutzman, Hayley N.
AU - Tsakalos, Golsum
AU - Zende, Rahul R.
AU - Zlavog, Bianca S.
AU - Abbafati, Cristiana
AU - Abebo, Zeleke Hailemariam
AU - Abolhassani, Hassan
AU - Abrigo, Michael R.M.
AU - Ahmed, Muktar Beshir
AU - Akinyemi, Rufus Olusola
AU - Alam, Khurshid
AU - Ali, Saqib
AU - Alinia, Cyrus
AU - Alipour, Vahid
AU - Aljunid, Syed Mohamed
AU - Almasi, Ali
AU - Alvis-Guzman, Nelson
AU - Ancuceanu, Robert
AU - Andrei, Tudorel
AU - Andrei, Catalina Liliana
AU - Anjomshoa, Mina
AU - Antonio, Carl Abelardo T.
AU - Arabloo, Jalal
AU - Arab-Zozani, Morteza
AU - Aremu, Olatunde
AU - Atnafu, Desta Debalkie
AU - Ausloos, Marcel
AU - Avila-Burgos, Leticia
AU - Ayanore, Martin Amogre
AU - Azari, Samad
AU - Babalola, Tesleem Kayode
AU - Bagherzadeh, Mojtaba
AU - Baig, Atif Amin
AU - Bakhtiari, Ahad
AU - Banach, Maciej
AU - Banerjee, Srikanta K.
AU - Bärnighausen, Till Winfried
AU - Basu, Sanjay
AU - Baune, Bernhard T.
AU - Bayati, Mohsen
AU - Berman, Adam E.
AU - Bhageerathy, Reshmi
AU - Bhardwaj, Pankaj
AU - Bohluli, Mehdi
AU - Busse, Reinhard
AU - Cahuana-Hurtado, Lucero
AU - Cámera, Luis LA Alberto
AU - Castañeda-Orjuela, Carlos A.
AU - Catalá-López, Ferrán
AU - Cevik, Muge
AU - Chattu, Vijay Kumar
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - Dianatinasab, Mostafa
AU - Do, Hoa Thi
AU - Doshmangir, Leila
AU - El Tantawi, Maha
AU - Eskandarieh, Sharareh
AU - Esmaeilzadeh, Firooz
AU - Faraj, Anwar
AU - Farzadfar, Farshad
AU - Fischer, Florian
AU - Foigt, Nataliya A.
AU - Fullman, Nancy
AU - Gad, Mohamed M.
AU - Ghafourifard, Mansour
AU - Ghashghaee, Ahmad
AU - Gholamian, Asadollah
AU - Goharinezhad, Salime
AU - Grada, Ayman
AU - Haghparast Bidgoli, Hassan
AU - Hamidi, Samer
AU - Harb, Hilda L.
AU - Hasanpoor, Edris
AU - Hay, Simon I.
AU - Hendrie, Delia
AU - Henry, Nathaniel J.
AU - Herteliu, Claudiu
AU - Hole, Michael K.
AU - Hosseinzadeh, Mehdi
AU - Hostiuc, Sorin
AU - Huda, Tanvir M.
AU - Humayun, Ayesha
AU - Hwang, Bing Fang
AU - Ilesanmi, Olayinka Stephen
AU - Iqbal, Usman
AU - Irvani, Seyed Sina N.
AU - Islam, Sheikh Mohammed Shariful
AU - Islam, M. Mofizul
AU - Jahani, Mohammad Ali
AU - Jakovljevic, Mihajlo
AU - James, Spencer L.
AU - Javaheri, Zohre
AU - Jonas, Jost B.
AU - Joukar, Farahnaz
AU - Jozwiak, Jacek Jerzy
AU - Jürisson, Mikk
AU - Kalhor, Rohollah
AU - Karami Matin, Behzad
AU - Karimi, Salah Eddin
AU - Kayode, Gbenga A.
AU - Kazemi Karyani, Ali
AU - Kinfu, Yohannes
AU - Kisa, Adnan
AU - Kohler, Stefan
AU - Komaki, Hamidreza
AU - Kosen, Soewarta
AU - Kotlo, Anirudh
AU - Koyanagi, Ai
AU - Kumar, G. Anil
AU - Kusuma, Dian
AU - Lansingh, Van C.
AU - Larsson, Anders O.
AU - Lasrado, Savita
AU - Lee, Shaun Wen Huey
AU - Lim, Lee Ling
AU - Lozano, Rafael
AU - Magdy Abd El Razek, Hassan
AU - Mahdavi, Mokhtar Mahdavi
AU - Maleki, Shokofeh
AU - Malekzadeh, Reza
AU - Mansour-Ghanaei, Fariborz
AU - Mansournia, Mohammad Ali
AU - Mantovani, Lorenzo Giovanni
AU - Martinez, Gabriel
AU - Masoumi, Seyedeh Zahra
AU - Massenburg, Benjamin Ballard
AU - Menezes, Ritesh G.
AU - Mengesha, Endalkachew Worku
AU - Meretoja, Tuomo J.
AU - Meretoja, Atte
AU - Mestrovic, Tomislav
AU - Milevska Kostova, Neda
AU - Miller, Ted R.
AU - Mirica, Andreea
AU - Mirrakhimov, Erkin M.
AU - Moghadaszadeh, Masoud
AU - Mohajer, Bahram
AU - Mohamadi, Efat
AU - Mohammad Darwesh, Aso
AU - Mohammadian-Hafshejani, Abdollah
AU - Mohammadpourhodki, Reza
AU - Mohammed, Shafiu
AU - Mohebi, Farnam
AU - Mokdad, Ali H.
AU - Morrison, Shane Douglas
AU - Mosser, Jonathan F.
AU - Mousavi, Seyyed Meysam
AU - Muriithi, Moses K.
AU - Muthupandian, Saravanan
AU - Myint, Chaw Yin
AU - Naderi, Mehdi
AU - Nagarajan, Ahamarshan Jayaraman
AU - Nguyen, Cuong Tat
AU - Nguyen, Huong Lan Thi
AU - Nonvignon, Justice
AU - Noubiap, Jean Jacques
AU - Oh, In Hwan
AU - Olagunju, Andrew T.
AU - Olusanya, Jacob Olusegun
AU - Olusanya, Bolajoko Olubukunola
AU - Omar Bali, Ahmed
AU - Onwujekwe, Obinna E.
AU - Otstavnov, Stanislav S.
AU - Otstavnov, Nikita
AU - Owolabi, Mayowa Ojo
AU - Padubidri, Jagadish Rao
AU - Palladino, Raffaele
AU - Panda-Jonas, Songhomitra
AU - Pandey, Anamika
AU - Postma, Maarten J.
AU - Prada, Sergio I.
AU - Pribadi, Dimas Ria Angga
AU - Rabiee, Mohammad
AU - Rabiee, Navid
AU - Rahim, Fakher
AU - Ranabhat, Chhabi Lal
AU - Rao, Sowmya J.
AU - Rathi, Priya
AU - Rawaf, Salman
AU - Rawaf, David Laith
AU - Rawal, Lal
AU - Rawassizadeh, Reza
AU - Rezapour, Aziz
AU - Sabour, Siamak
AU - Sahraian, Mohammad Ali
AU - Salman, Omar Mukhtar
AU - Salomon, Joshua A.
AU - Samy, Abdallah M.
AU - Sanabria, Juan
AU - Santos, João Vasco
AU - Santric Milicevic, Milena M.
AU - Sao Jose, Bruno Piassi
AU - Savic, Miloje
AU - Schwendicke, Falk
AU - Senthilkumaran, Subramanian
AU - Sepanlou, Sadaf G.
AU - Serván-Mori, Edson
AU - Setayesh, Hamidreza
AU - Shaikh, Masood Ali
AU - Sheikh, Aziz
AU - Shibuya, Kenji
AU - Shrime, Mark G.
AU - Simonetti, Biagio
AU - Singh, Jasvinder A.
AU - Singh, Pushpendra
AU - Skryabin, Valentin Yurievich
AU - Soheili, Amin
AU - Soltani, Shahin
AU - Ștefan, Simona Cătălina
AU - Tabarés-Seisdedos, Rafael
AU - Topor-Madry, Roman
AU - Tovani-Palone, Marcos Roberto
AU - Tran, Bach Xuan
AU - Travillian, Ravensara
AU - Undurraga, Eduardo A.
AU - Valdez, Pascual R.
AU - van Boven, Job F.M.
AU - Vasankari, Tommi Juhani
AU - Violante, Francesco S.
AU - Vlassov, Vasily
AU - Vos, Theo
AU - Wolfe, Charles D.A.
AU - Wu, Junjie
AU - Yaya, Sanni
AU - Yazdi-Feyzabadi, Vahid
AU - Yip, Paul
AU - Yonemoto, Naohiro
AU - Younis, Mustafa Z.
AU - Yu, Chuanhua
AU - Zaidi, Zoubida
AU - Zaman, Sojib Bin
AU - Zastrozhin, Mikhail Sergeevich
AU - Zhang, Zhi Jiang
AU - Zhao, Yingxi
AU - Murray, Christopher J.L.
AU - Dieleman, Joseph L.
N1 - Funding Information: R O Akinyemi acknowledges supports from the US National Institutes of Health (NIH; Grant U01HG010273) as part of the H3Africa Consortium and a Global Challenges Research Fund (GCRF) fellowship grant (FLR/R1/191813) from the UK Royal Society and the African Academy of Sciences. S M Aljunid acknowledges International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia and Department of Health Policy and Management, and Faculty of Public Health, Kuwait University for the approval and support to participate in this research project. M Ausloos acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084). T W B?rnighausen acknowledges support from the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research. S I Hay acknowledges primary support from the Bill & Melinda Gates Foundation (grant OPP1132415). Claudiu Herteliu acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084) and from a grant co-funded by European Fund for Regional Development through Operational Program for Competitiveness (project ID P_40_382). B-F Hwang acknowledges support from China Medical University (CMU 107-Z-04), Taichung, Taiwan. S M S Islam acknowledges funding from the National Heart Foundation of Australia and Deakin University. M Jakovljevic acknowledges the Ministry of Education Science and Technological Development of the Republic of Serbia for co-funding for the Serbian part of this Global Burden of Disease (GBD) contribution (grant OI 175 014). A M Samy acknowledges support from a fellowship from the Egyptian Fulbright Mission Program. M M Santric Milicevic acknowledges support from The Ministry of Education, Science and Technological Development, Serbia (contract number 175087). A Sheikh acknowledges support from Health Data Research UK. R Tabar?s-Seisdedos acknowledges support in part from Generalitat Valenciana (grant number PROMETEOII/2015/021) and from Instituto de Salud Carlos III-La Federaci?n Espa?ola de Enfermedades Raras (national grant PI17/00719). J F M van Boven acknowledges support from the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, University of Groningen, Groningen Netherlands. S B Zaman acknowledges the Australian Government research training programme for providing a scholarship in support of his academic career. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Funding Information: C A T Antonio reports personal fees from Johnson & Johnson (Philippines) outside of the submitted work. A E Berman reports personal fees from Biosense Webster outside of the submitted work. S L James reports grants from Sanofi Pasteur and future employment with Genentech/Roche outside of the submitted work. J J Jóźwiak reports personal fees from VALEANT, ALAB Laboratoria, and AMGEN outside of the submitted work. M J Postma reports grants and personal fees from MSD, GlaxoSmithKline (GSK), Pfizer, Boehringer Ingelheim, Novavax, Bristol-Myers Squibb, AstraZeneca, Sanofi, Seqirus, and IQVIA; grants from Bayer, BioMerieux, WHO, the European Union? FIND, Antilope, DIKTI, LPDP, and BUDI; personal fees from Novartis, Pharmerit, and Quintiles; holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen; and is advisor to Asc Academics outside of the submitted work. M Savic reports employment with the GSK group of companies and hold restricted shares in the GSK group of companies. M G Shrime reports grants from Mercy Ships and Damon Runyon Cancer Research Foundation outside of the submitted work. J A Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology, and Simply Speaking; participating in the Speaker's Bureau at Simply Speaking; owning stock options in Amarin Pharmaceuticals and Viking Pharmaceuticals; membership in the FDA Arthritis Advisory Committee, Veterans Affairs Rheumatology Field Advisory Committee, and in the Steering Committee of Outcome Measures in Rheumatology (OMERACT), and acting as Editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis outside of the submitted work. All other authors declare no competing interests. Funding Information: Although economic development is associated with reducing the domestic health financing burden that is funded by out-of-pocket spending, considerable variation exists in this association ( figure 5A ). For any one level of GDP per capita, a sizeable range of the fraction of domestic health spending is financed by out-of-pocket spending, suggesting that economic development does not solely determine the transition away from household financing. Additionally, large variation exists across countries in the association between rate of change in the fraction of domestic health spending that is out-of-pocket and the rate of change in the proportion of households with catastrophic health expenditure ( figure 5B ). A reliance on domestic government, prepaid, and pooled health financing is a means towards achieving universal health coverage and financial risk protection. Globally, this fraction contributing to universal health coverage ranges from 6·7% (95% UI 4·5–9·1) in Afghanistan to 100% (100–100) in Greenland (for more details see the WHO Global Health Data Exchange). Publisher Copyright: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Funding Information: R O Akinyemi acknowledges supports from the US National Institutes of Health (NIH; Grant U01HG010273) as part of the H3Africa Consortium and a Global Challenges Research Fund (GCRF) fellowship grant (FLR/R1/191813) from the UK Royal Society and the African Academy of Sciences. S M Aljunid acknowledges International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia and Department of Health Policy and Management, and Faculty of Public Health, Kuwait University for the approval and support to participate in this research project. M Ausloos acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084). T W Bärnighausen acknowledges support from the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research. S I Hay acknowledges primary support from the Bill & Melinda Gates Foundation (grant OPP1132415). Claudiu Herteliu acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084) and from a grant co-funded by European Fund for Regional Development through Operational Program for Competitiveness (project ID P_40_382). B-F Hwang acknowledges support from China Medical University (CMU 107-Z-04), Taichung, Taiwan. S M S Islam acknowledges funding from the National Heart Foundation of Australia and Deakin University. M Jakovljevic acknowledges the Ministry of Education Science and Technological Development of the Republic of Serbia for co-funding for the Serbian part of this Global Burden of Disease (GBD) contribution (grant OI 175 014). A M Samy acknowledges support from a fellowship from the Egyptian Fulbright Mission Program. M M Santric Milicevic acknowledges support from The Ministry of Education, Science and Technological Development, Serbia (contract number 175087). A Sheikh acknowledges support from Health Data Research UK. R Tabarés-Seisdedos acknowledges support in part from Generalitat Valenciana (grant number PROMETEOII/2015/021) and from Instituto de Salud Carlos III-La Federación Española de Enfermedades Raras (national grant PI17/00719). J F M van Boven acknowledges support from the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, University of Groningen, Groningen Netherlands. S B Zaman acknowledges the Australian Government research training programme for providing a scholarship in support of his academic career. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Funding Information: C A T Antonio reports personal fees from Johnson & Johnson (Philippines) outside of the submitted work. A E Berman reports personal fees from Biosense Webster outside of the submitted work. S L James reports grants from Sanofi Pasteur and future employment with Genentech/Roche outside of the submitted work. J J Jóźwiak reports personal fees from VALEANT, ALAB Laboratoria, and AMGEN outside of the submitted work. M J Postma reports grants and personal fees from MSD, GlaxoSmithKline (GSK), Pfizer, Boehringer Ingelheim, Novavax, Bristol-Myers Squibb, AstraZeneca, Sanofi, Seqirus, and IQVIA; grants from Bayer, BioMerieux, WHO, the European Union? FIND, Antilope, DIKTI, LPDP, and BUDI; personal fees from Novartis, Pharmerit, and Quintiles; holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen; and is advisor to Asc Academics outside of the submitted work. M Savic reports employment with the GSK group of companies and hold restricted shares in the GSK group of companies. M G Shrime reports grants from Mercy Ships and Damon Runyon Cancer Research Foundation outside of the submitted work. J A Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology, and Simply Speaking; participating in the Speaker's Bureau at Simply Speaking; owning stock options in Amarin Pharmaceuticals and Viking Pharmaceuticals; membership in the FDA Arthritis Advisory Committee, Veterans Affairs Rheumatology Field Advisory Committee, and in the Steering Committee of Outcome Measures in Rheumatology (OMERACT), and acting as Editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis outside of the submitted work. All other authors declare no competing interests. Funding Information: Although economic development is associated with reducing the domestic health financing burden that is funded by out-of-pocket spending, considerable variation exists in this association ( figure 5A ). For any one level of GDP per capita, a sizeable range of the fraction of domestic health spending is financed by out-of-pocket spending, suggesting that economic development does not solely determine the transition away from household financing. Additionally, large variation exists across countries in the association between rate of change in the fraction of domestic health spending that is out-of-pocket and the rate of change in the proportion of households with catastrophic health expenditure ( figure 5B ). A reliance on domestic government, prepaid, and pooled health financing is a means towards achieving universal health coverage and financial risk protection. Globally, this fraction contributing to universal health coverage ranges from 6·7% (95% UI 4·5–9·1) in Afghanistan to 100% (100–100) in Greenland (for more details see the WHO Global Health Data Exchange). Publisher Copyright: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2020/9/5
Y1 - 2020/9/5
N2 - Background: Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. Methods: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 until 2030. We report all spending estimates in inflation-adjusted 2019 US$, unless otherwise stated. Findings: Since the development and implementation of the SDGs in 2015, global health spending has increased, reaching $7·9 trillion (95% uncertainty interval 7·8–8·0) in 2017 and is expected to increase to $11·0 trillion (10·7–11·2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was $20·2 billion (17·0–25·0) and on tuberculosis it was $10·9 billion (10·3–11·8), and in malaria-endemic countries spending on malaria was $5·1 billion (4·9–5·4). Development assistance for health was $40·6 billion in 2019 and HIV/AIDS has been the health focus area to receive the highest contribution since 2004. In 2019, $374 million of DAH was provided for pandemic preparedness, less than 1% of DAH. Although spending has increased across HIV/AIDS, tuberculosis, and malaria since 2015, spending has not increased in all countries, and outcomes in terms of prevalence, incidence, and per-capita spending have been mixed. The proportion of health spending from pooled sources is expected to increase from 81·6% (81·6–81·7) in 2015 to 83·1% (82·8–83·3) in 2030. Interpretation: Health spending on SDG3 priority areas has increased, but not in all countries, and progress towards meeting the SDG3 targets has been mixed and has varied by country and by target. The evidence on the scale-up of spending and improvements in health outcomes suggest a nuanced relationship, such that increases in spending do not always results in improvements in outcomes. Although countries will probably need more resources to achieve SDG3, other constraints in the broader health system such as inefficient allocation of resources across interventions and populations, weak governance systems, human resource shortages, and drug shortages, will also need to be addressed. Funding: The Bill & Melinda Gates Foundation.
AB - Background: Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. Methods: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 until 2030. We report all spending estimates in inflation-adjusted 2019 US$, unless otherwise stated. Findings: Since the development and implementation of the SDGs in 2015, global health spending has increased, reaching $7·9 trillion (95% uncertainty interval 7·8–8·0) in 2017 and is expected to increase to $11·0 trillion (10·7–11·2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was $20·2 billion (17·0–25·0) and on tuberculosis it was $10·9 billion (10·3–11·8), and in malaria-endemic countries spending on malaria was $5·1 billion (4·9–5·4). Development assistance for health was $40·6 billion in 2019 and HIV/AIDS has been the health focus area to receive the highest contribution since 2004. In 2019, $374 million of DAH was provided for pandemic preparedness, less than 1% of DAH. Although spending has increased across HIV/AIDS, tuberculosis, and malaria since 2015, spending has not increased in all countries, and outcomes in terms of prevalence, incidence, and per-capita spending have been mixed. The proportion of health spending from pooled sources is expected to increase from 81·6% (81·6–81·7) in 2015 to 83·1% (82·8–83·3) in 2030. Interpretation: Health spending on SDG3 priority areas has increased, but not in all countries, and progress towards meeting the SDG3 targets has been mixed and has varied by country and by target. The evidence on the scale-up of spending and improvements in health outcomes suggest a nuanced relationship, such that increases in spending do not always results in improvements in outcomes. Although countries will probably need more resources to achieve SDG3, other constraints in the broader health system such as inefficient allocation of resources across interventions and populations, weak governance systems, human resource shortages, and drug shortages, will also need to be addressed. Funding: The Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85085626757&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)30608-5
DO - 10.1016/S0140-6736(20)30608-5
M3 - Review article
C2 - 32334655
AN - SCOPUS:85085626757
SN - 0140-6736
VL - 396
SP - 693
EP - 724
JO - The Lancet
JF - The Lancet
IS - 10252
ER -